1. Home
  2. EIG vs MLYS Comparison

EIG vs MLYS Comparison

Compare EIG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIG
  • MLYS
  • Stock Information
  • Founded
  • EIG 2000
  • MLYS 2019
  • Country
  • EIG United States
  • MLYS United States
  • Employees
  • EIG N/A
  • MLYS N/A
  • Industry
  • EIG Property-Casualty Insurers
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EIG Finance
  • MLYS Health Care
  • Exchange
  • EIG Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • EIG 1.0B
  • MLYS 890.6M
  • IPO Year
  • EIG 2007
  • MLYS 2023
  • Fundamental
  • Price
  • EIG $43.24
  • MLYS $15.48
  • Analyst Decision
  • EIG Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • EIG 1
  • MLYS 5
  • Target Price
  • EIG $58.00
  • MLYS $31.00
  • AVG Volume (30 Days)
  • EIG 218.1K
  • MLYS 900.8K
  • Earning Date
  • EIG 10-29-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • EIG 2.98%
  • MLYS N/A
  • EPS Growth
  • EIG N/A
  • MLYS N/A
  • EPS
  • EIG 4.10
  • MLYS N/A
  • Revenue
  • EIG $889,500,000.00
  • MLYS N/A
  • Revenue This Year
  • EIG $0.86
  • MLYS N/A
  • Revenue Next Year
  • EIG $0.80
  • MLYS N/A
  • P/E Ratio
  • EIG $10.47
  • MLYS N/A
  • Revenue Growth
  • EIG 2.32
  • MLYS N/A
  • 52 Week Low
  • EIG $38.19
  • MLYS $8.24
  • 52 Week High
  • EIG $54.44
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • EIG 50.15
  • MLYS 59.94
  • Support Level
  • EIG $42.73
  • MLYS $14.53
  • Resistance Level
  • EIG $43.48
  • MLYS $15.79
  • Average True Range (ATR)
  • EIG 0.65
  • MLYS 0.89
  • MACD
  • EIG 0.29
  • MLYS 0.14
  • Stochastic Oscillator
  • EIG 71.96
  • MLYS 90.31

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: